Note from the CEO

Global markets are on tenterhooks ahead of the release of the US Federal Open Market Committee’s latest interest rate decision, due early Thursday morning (Australian time).

A third consecutive rate hike of 75 basis points above the current target range of 2.25% to 2.50% is widely predicted, but it’s possible an inflation-panicked Fed will instead opt for a full 100-basis-point leap – something that hasn’t happened since the 1980s.

Whatever the outcome of the meeting, most leading economists now expect the US central bank to lift its benchmark policy rate above 4% and then hold it there beyond 2023, according to a survey published this week in the London Financial Times.

And many observers – including ANZ Bank – believe the rate will peak at 5% or higher, i.e. double its current level.

In Australia, some economists are already predicting that the Reserve Bank of Australia will be forced to start slashing rates as early as next year to stave off recession. However, the RBA’s options will be limited if the Fed is still moving aggressively in the opposite direction. Click here to read the full CEO note.

Historically, the healthcare sector has proven to be largely immune to recession. For example, demand in the sector’s biggest market, the global US$280 billion oncology industry (as at 2021), is predominantly driven by the demand for therapies and the rapid innovation that is happening in the field right now.

We have an upcoming webinar with a company that is helping move the cancer conversation from ‘fight’ towards ‘cure’. Prescient Therapeutics Limited (ASX: PTX) is a biotech innovator that will be unveiling the second component of the CellPryme cell therapy enhancement platform, CellPryme-A, at the prestigious CAR-TCR Summit in Boston this week.

On Tuesday, 27th September at 12pm (AEST), we will be joined by Prescient’s CEO Steven Yatomi-Clarke and Senior VP Dr Rebecca Lim for what we think will be a fascinating conversation for potential investors. Click here to attend.

Patrick Nelson
Managing Director
Reach Markets

Pepper Money

ASX: PPM | Financial Services

When Katana Asset Management’s Romano Sala Tenna presented on The Insider: Meet the Fund Manager in May, he selected financial services provider Pepper Money as one of his three favourite stocks. It’s a business Romano believes has first-rate management and top-notch culture, which is behind its ability to generate strong cash flow.

Click here to view the fund manager's review.

Why a huge opportunity awaits first movers in budding sector

The Australian pharma landscape is in for a notable change with the down-scheduling of low-dose cannabidiol (CBD) products to Schedule 3 (S3) or ‘pharmacist only medicine’ – and one health and wellness innovator’s proven capability to take brands to market ‘first and fast’ puts it in a unique position to be a pioneer in the industry.

Mining Services Business*

Fast-growing autonomous remote mining services business with blue-chip partners, advanced tech and a unique competitive advantage.

Register to get access to investment opportunities as they open.

Major weapons upgrade in the $1 trillion fight against cancer

There’s a 50-50 chance you’ll get cancer at some point. Already the world’s second leading cause of death and of years of life lost, the global cancer burden is expected to grow 47% between 2020 and 2040, to about 29 million cases annually.

Good as gold: Drilling begins at FEG’s highly prospective Woyla

Just over a week after the Indonesian Government granted its approval in a milestone decision, the first-ever drill rig to enter Woyla has been fired up and drilling has begun at the highly prospective copper-gold project.

Fundie reveals strategy that saw his fund grow when indexes fell

If ever an investment group embodied the phrase ‘an oldie but a goodie’, it’s Hancock & Gore – from its roots as a blossoming sawmill business in 1867 to its market-outperforming status in modern times.

Like it or not, this CEO paints a scarily real picture of our future

Investors are known for their interest in future tech and their appreciation of fine art – but would the love remain if these areas were combined? One enterprising CEO may just have the answer.

Trade of the Week Ratio Put Backspread - XJO 

This week’s trade of the week comes from the trading scanner built into the Implied Volatility (Elite) platform. There are many drivers to the S&P/ASX200 (ASX: XJO) – in short, the index is based on the demand and supply of Australian companies and their individual profit, collated into an index. View Trade of the Week.

Special Event: Prescient Live Briefing

Please join Prescient CEO and managing director Steven Yatomi-Clarke for an investor briefing.

In the session, Steven will discuss how PTX will be unveiling the second component of the CellPryme cell therapy enhancement platform, CellPryme-A, at the prestigious CAR-TCR Summit in Boston this week.

The Insider: Meet the CEOs

Please join Prescient CEO and MD Steven Yatomi-Clarke and Aerometrex MD Steve Masters.

In the session, Steven and Steve will provide a succinct overview of big things their companies are doing, followed by an interactive Q&A.

More Upcoming Events

Wellnex Live Investor Briefing

Thu 29th Sep

Attend Session

The original sender of this email is Reach* and the email is, along with any attachments, confidential. The contents can only be used by the intended recipient. It can be corrupted in transmission, and the onus is on the recipient to check for and remove viruses. This statement should not be removed and should be filed along with any printed record of the email. If you are not the intended recipient, confidentiality is not waived, and you must immediately tell us by email or telephone +61 3 8080 5795 and delete it permanently from your computer. The original sender retains copyright in the contents and attachments, and any unauthorised use may result in legal action. The content is based on information obtained from sources believed to be reliable, but no independent verification has been made, nor is its accuracy guaranteed. Except to the extent required by law, Reach nor any of its employee’s agents or contractors makes any representation as to the accuracy or fitness for purpose of the information in this statement.

Any advice contained in this communication is general only and does not consider your objectives, financial situation or needs, and you should consider whether it's appropriate for you. This might mean that you need to seek personal advice from a representative authorised to provide personal advice. If you are thinking about acquiring a financial product, you should consider our Financial Services Guide (FSG) including the Privacy Statement at www.reachmarkets.com.au and the relevant Product Disclosure Statement or Prospectus (if there is one available) to understand the features, risks and returns associated with the investment. Reach may have a material interest in and may earn fees or brokerage from any securities referred to in business or in which we seek to do business with. Please refer to the relevant offer documents for full details.

Trading options is not suitable for everyone. There is a risk that you can lose more than the value of a trade or its underlying assets. You should only act on the information we provide if you are confident that you fully understand what you are doing. Past returns do not always indicate future returns, and it is also possible to make significant losses. There is always a risk of loss when trading and investing.

*Reach refers to Reach Markets Pty Ltd (ABN 36 145 312 232) (CAR No: 431191), Reach Corporate Pty Ltd (ABN 76 638 960 540) (CAR No:1281636), Reach Trading Pty Ltd (ABN 16 615 714 442) (CAR No.1265855), R Corporate Pty Ltd (ABN 50643404871) (CAR No. 1290551) of Reach Financial Group Pty Ltd (ABN 17 090 611 680) who hold an Australian Financial Services Licence (AFSL) 333297.

Level 7
440 Collins Street
Melbourne

VIC 3000